Daniel Poon

Daniel Poon has extensive experience in the field of medicinal chemistry. Daniel worked at RAPT Therapeutics from 2019 to the present, initially as the Director of Medicinal Chemistry before being promoted to Senior Director in February 2021. Prior to this, they spent over a decade at Novartis, where they held the position of Associate Director-Senior Investigator I. During their time at Novartis, they led important chemistry programs such as the mut-B-RAF program, which led to the development of LGX818 (encorafenib) for the treatment of metastatic melanoma, and the ERK1/2 program, which identified LTT462 currently in Phase I trials. Before joining Novartis, they worked as a Principal Scientist at Chiron Corporation from 1999 to 2006.

Daniel Poon obtained a Ph.D. in Organic Chemistry from UC Irvine, where they attended from 1991 to 1996. Following that, they pursued a Postdoctoral Fellowship in Organic Chemistry at Colorado State University from 1997 to 1999.